Accurate, Actionable, and Affordable
Early Cancer Diagnostic Tests
MiRXES’ microRNA-centric liquid biopsy tests complement existing standard diagnostics to enable non-invasive cancer screening and early detection so that timely, life-saving care can be provided to patients.
The world’s first approved* microRNA blood test for early detection of gastric cancer.
* CE IVD marked and approved for IVD use by Singapore’s Health Sciences Authority.
MiRXES GASTROClear is a qPCR-based diagnostic test kit that measures 12 microRNA biomarkers linked to gastric cancer and calculates a cancer risk score for each patient using a proprietary algorithm that has been clinically validated.
The test was developed by MiRXES in collaboration with the Singapore Gastric Cancer Consortium (SGCC), the Diagnostic Development (DxD) Hub of Singapore’s Agency for Science, Technology and Research (A*STAR), National University Hospital (NUH), and Tan Tock Seng Hospital (TTSH).
1 , et al. Development and validation of a serum microRNA biomarker panel for detecting gastric cancer in a high-risk population.
GASTROClear test can be ordered by healthcare providers through MiRXES partner diagnostic labs
Tan Tock Seng Hospital (TTSH)
Molecular Diagnostic Lab (MDL)
National University Hospital (NUH)
Molecular Diagnosis Centre (MDC)
GASTROClear Order Information and Product Support
For clinical diagnostic labs and healthcare providers only.
The science and story